Filtered By:
Therapy: Chemotherapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 72831 results found since Jan 2013.

High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders.
CONCLUSION: HIV positive patients receiving treatment for lymphoproliferative disorders suffer from a high incidence of infections and associated mortality risk. Tailored secondary prophylaxis is beneficial and should be considered in this setting. PMID: 28558641 [PubMed - as supplied by publisher]
Source: Current HIV Research - May 30, 2017 Category: Infectious Diseases Authors: Calcagno A, Lucchini A, Caracciolo D, Balbiano R, Bracchi M, Sordella F, Gregori G, Lipani F, Audagnotto S, Chiriotto M, Cavaglià G, Ghisetti V, Di Perri G, Bonora S Tags: Curr HIV Res Source Type: research

Concurrence of Talaromycosis and Kaposi Sarcoma in a HIV-Infected Patient: A Case Report.
CONCLUSIONS: Severe medical conditions such as Kaposi sarcoma and talaromycosis may coexist in HIV-infected patients and pose an increased risk of mortality. Etiological diagnosis and treatment are the key to successful management of HIVinfected patients with these concurrent conditions. PMID: 33153422 [PubMed - as supplied by publisher]
Source: Current HIV Research - November 5, 2020 Category: Infectious Diseases Authors: Miao X, Ye H, Yang S, Su F Tags: Curr HIV Res Source Type: research

Immunosuppressive Effects of Cancer Treatment Increase Mortality in People With HIV Immunosuppressive Effects of Cancer Treatment Increase Mortality in People With HIV
Adults with HIV whose cancers are treated with chemotherapy or radiotherapy experience significant reductions in CD4 count, which are linked to increased mortality, compared with those who have surgery or other treatment, according to findings from an observational study.Reuters Health Information
Source: Medscape Hiv-Aids Headlines - December 11, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Nelfinavir is effective in inhibiting the multiplication and aspartic peptidase activity of Leishmania species, including strains obtained from HIV-positive patients
Conclusions The present data contribute to the study of the effect of HIV PIs on Leishmania infection and add new insights into the possibility of exploiting aspartic peptidases as promising targets in order to generate novel medications to treat leishmaniasis.
Source: Journal of Antimicrobial Chemotherapy - January 11, 2013 Category: Microbiology Authors: Santos, L. O., Vitorio, B. S., Branquinha, M. H., Pedroso e Silva, C. M., Santos, A. L. S., d'Avila-Levy, C. M. Tags: Original research Source Type: research

GSE165615 Post-transcriptional regulation can harness genome instability and provide phenotypic robustness during fitness gain in the human parasite Leishmania donovani
Contributors : Laura Piel ; Hugo Varet ; Rachel Legendre ; Caroline Proux ; Pascale Pescher ; Gerald Sp äthSeries Type : Expression profiling by high throughput sequencingOrganism : Leishmania donovaniGenome instability has been recognized as a driver in Leishmania fitness gain in response to environmental change or chemotherapy. How genome instability generates beneficial phenotypes despite potential deleterious gene dosage effects is unknown. Here we address this important open question applying experimental evolution and integrative systems approaches on parasites adapting to in vitro culture. Phenotypic analyses of pa...
Source: GEO: Gene Expression Omnibus - February 22, 2022 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Leishmania donovani Source Type: research

There Is No Cure for HIV —But Scientists May Be Getting Closer
Cure isn’t a word normally used in the context of AIDS. For most of the 35 years since HIV, the virus responsible for the disease, was first identified, doctors have viewed the notion of a cure as more fantasy than fact. That’s because HIV is a virus unlike any other. It disables the very immune cells that are supposed to destroy it and also sequesters itself in the body’s cells, staging the ultimate deadly ambush whenever the immune defense’s guard comes down, months or sometimes even years later. Yet for the first time in the HIV epidemic that currently affects nearly 37 million people worldwide, ...
Source: TIME: Health - March 8, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized AIDS/HIV Source Type: news

A Man May Be Cleared of HIV for the Second Time in History. Here ’s What That Means
A man in London has become only the second person to achieve remission from HIV infection, researchers from the UK reported Tuesday. The therapy responsible has worked on only one other person who is considered to be “cured” of HIV: Timothy Ray Brown, who still does not show signs of the virus in his body after more than 10 years. Here’s what to know about the landmark case. How did it happen? In a letter published in the journal Nature, researchers led by Ravindra Gupta from the University of Cambridge London and Imperial College London and his colleagues say that they used a treatment similar to the one...
Source: TIME: Health - March 5, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized HIV/AIDS Source Type: news

HIV Did Not Stop Me From Having a Biological Child
On Monday, April 15, 2013, at 8:00 a.m., my life changed forever. My wife, Kasiah, and I welcomed our first child, a healthy girl named Finley Elizabeth Banks, into this world. She was perfect. But the journey to have a healthy, HIV-free biological child began many years before Finley’s birth. MoreFederal Appeals Court Strikes Down Utah's Gay Marriage Ban NBC NewsJessica N. Turner: Moms, Put on That Swimsuit Huffington PostShould the Cops Get to Look at Your Cellphone? NBC NewsParty's Over? GOP's Insurgents Take More Punches NBC NewsUruguay eliminates Italy; Did Suarez bite again? Sports IllustratedIn 1981, when I wa...
Source: TIME.com: Top Science and Health Stories - June 25, 2014 Category: Consumer Health News Authors: clairehoworth Tags: Uncategorized AIDS research Family & Parenting Fatherhood HIV medicine Science Source Type: news

Comparison of the Antiviral Activity of Bictegravir Against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.
Abstract We compared the activity of the integrase inhibitor bictegravir against HIV-1 and HIV-2 using a culture-based, single-cycle assay. EC50 values ranged from 1.2 to 2.5 nM for nine HIV-1 isolates and 1.4 to 5.6 nM for 15 HIV-2 isolates. HIV-2 integrase mutants G140S/Q148R and G140S/Q148H were 34- and 110-fold resistant to bictegravir, respectively; other resistance-associated mutations conferred ≤5-fold changes in bictegravir susceptibility. Our findings indicate that bictegravir-based ART should be evaluated in HIV-2-infected individuals. PMID: 30803972 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - February 25, 2019 Category: Microbiology Authors: Smith RA, Raugi DN, Wu VH, Zavala CG, Song J, Diallo KM, Seydi M, Gottlieb GS, University of Washington-Dakar HIV-2 Study Group Tags: Antimicrob Agents Chemother Source Type: research

Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts
Conclusions Initiating cART during PHI represents a major opportunity to reduce HIV reservoirs and achieve optimal immune reconstitution.
Source: Journal of Antimicrobial Chemotherapy - April 12, 2013 Category: Microbiology Authors: Hocqueloux, L., Avettand-Fenoel, V., Jacquot, S., Prazuck, T., Legac, E., Melard, A., Niang, M., Mille, C., Le Moal, G., Viard, J.-P., Rouzioux, C., on behalf of the AC32 (Coordinated Action on HIV Reservoirs) of the Agence Nationale de Recherches sur le Tags: Original research Source Type: research

HIV-2 viral tropism influences CD4+ T cell count regardless of viral load
Conclusions The presence of X4-tropic viruses in HIV-2 infection is associated with low CD4+ cell counts, regardless of antiretroviral treatment. Along with CD4+ cell counts, viral tropism testing may assist decisions about when to initiate antiretroviral therapy in HIV-2-infected individuals.
Source: Journal of Antimicrobial Chemotherapy - July 16, 2014 Category: Microbiology Authors: Trevino, A., Soriano, V., Poveda, E., Parra, P., Cabezas, T., Caballero, E., Roc, L., Rodriguez, C., Eiros, J. M., Lopez, M., De Mendoza, C., on behalf of the HIV-2 Spanish Study Group, Rodriguez, del Romero, Tuset, Marcaida, Ocete, Tuset, Caballero, Moli Tags: Original research Source Type: research

Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999-2011
Conclusions During 1999–2011, GT use among antiretroviral-naive patients became more common, but a quarter of patients in recent years remained untested. The frequency of mDRMs remained stable over time at about 15%.
Source: Journal of Antimicrobial Chemotherapy - July 13, 2015 Category: Microbiology Authors: Buchacz, K., Young, B., Palella, F. J., Armon, C., Brooks, J. T., on behalf of the HIV Outpatient Study (HOPS) investigators, on behalf of the HIV Outpatient Study (HOPS) investigators, Buchacz, Brooks, Durham, Hays, Wood, Hankerson, Hart, Subramanian, Ar Tags: Original research Source Type: research

The demise of multidrug-resistant HIV-1: the national time trend in Portugal
Conclusions The prevalence of multidrug-resistant HIV-1 is decreasing over time in Portugal, reflecting the increasing efficiency of HAART and the availability of new drugs. Therefore, in designing a new drug, safety and practical aspects, e.g. less toxicity and ease of use, may need more attention than focusing mainly on efficacy against resistant strains.
Source: Journal of Antimicrobial Chemotherapy - March 11, 2013 Category: Microbiology Authors: Vercauteren, J., Theys, K., Carvalho, A. P., Valadas, E., Duque, L. M., Teofilo, E., Faria, T., Faria, D., Vera, J., Aguas, M. J., Peres, S., Mansinho, K., Vandamme, A.-M., Camacho, R. J., on behalf of the Portuguese HIV-1 Resistance Study Group, Mansinho Tags: Original research Source Type: research

Cotrimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.
Abstract Cotrimoxazole reduces mortality in HIV-infected adults with tuberculosis (TB), and in vitro data suggest potential anti-mycobacterial activity of cotrimoxazole. We aimed to evaluate whether prophylaxis with cotrimoxazole is associated with a decreased risk of incident TB in SHCS participants. We determined the incidence of TB per 1000 person-years from January 1992 to December 2012. Rates were analyzed separately in participants with current or no previous antiretroviral treatment (ART) using Poisson regression adjusted for CD4 cell count, sex, region of origin, injecting drug use, and age. 13,431 cohort ...
Source: Antimicrobial Agents and Chemotherapy - February 10, 2014 Category: Microbiology Authors: Hasse B, Walker AS, Fehr J, Furrer H, Hoffmann M, Battegay M, Calmy A, Fellay J, Di Benedetto C, Weber R, Ledergerber B, the Swiss HIV Cohort Study Tags: Antimicrob Agents Chemother Source Type: research

Population pharmacokinetics and pharmacogenetics analysis of Rilpivirine in HIV-1 infected individuals.
CONCLUSION: The variability in RPV pharmacokinetics appears lower than for most other antiretroviral drugs. However, under the standard regimen of 25 mg daily, a significant amount of patients might be underdosed. It remains to be investigated whether the underexposure has an impact of the development of resistance on maintenance therapy. PMID: 27799217 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - October 30, 2016 Category: Microbiology Authors: Aouri M, Barcelo C, Guidi M, Rotger M, Cavassini M, Hizrel C, Buclin T, Decosterd LA, Csajka C, Swiss HIV Cohort Study. Tags: Antimicrob Agents Chemother Source Type: research